Australia markets closed

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
304.75+6.88 (+2.31%)
At close: 04:00PM EDT
303.99 -0.76 (-0.25%)
Pre-market: 04:20AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close297.87
Bid0.00 x 800
Ask0.00 x 800
Day's range300.67 - 305.47
52-week range233.01 - 325.19
Avg. volume1,253,668
Market cap78.348B
Beta (5Y monthly)0.48
PE ratio (TTM)23.09
EPS (TTM)13.20
Earnings date03 May 2023 - 08 May 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est334.08
  • Zacks

    Halozyme Therapeutics (HALO) Down 34.4% Since Last Earnings Report: Can It Rebound?

    Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Motley Fool

    This Cathie Wood Stock Could Nearly Double, According to Wall Street

    One stock that could ride the market rally is CRISPR Therapeutics (NASDAQ: CRSP). This biotech is seeking to develop breakthrough therapies for difficult-to-treat illnesses using gene editing, and the company's focus in this area earned it a prominent place in the Ark Genomic Revolution ETF, an exchange-traded fund overseen by Cathie Wood. Wood isn't the only one on Wall Street who likes CRISPR.

  • Motley Fool

    This Is My Highest-Conviction Stock to Own in 2023 and Beyond

    While one could say the same about many biotech companies, Vertex has an advantage very few of its peers do: For CF patients, it's the only game in town. Vertex markets the only medicines that target the underlying causes of CF. In 2022, the company's revenue of $8.93 billion jumped by 18% year over year.